Notice to Sole Source - Roche COBAS 5800 reagents kits for HBV and HCV

NOTICE OF INTENT TO ISSUE AN ORDER. This is not a request for competitive proposals/quotes. The Centers for Disease Control and Prevention (CDC) hereby announces its intent to issue a sole source order to Roche Diagnostics Corporation, 9115 Hague RD, Indianapolis, Indiana 46256-1025, United States, for Roche COBAS 5800 reagents kits for HBV and HCV. The NAICS code for this acquisition is 334516 Analytical Laboratory Instrument Manufacturing, with a size standard of 1,000.

Subject to the Availability of Funds

Roche COBAS 5800 reagents kits for HBV and HCV

A determination by the Government not to compete this proposed action will be based on responses to this notice and is solely in the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. All vendors must be registered in the System for Award Management (SAM) at www.sam.gov , prior to an award of a federal contract.

This action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement or submit quotations. This is not a request for competitive quotations; however, the Government will review any/all product, capabilities, and pricing information submitted prior to the closure of this notice.

A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.

Responsible sources that believe they possess the expertise and capabilities identified above are hereby afforded the opportunity to submit to the Contracting Officer by the due date of this notice, their written capabilities statement and pricing information in the format they choose, not to exceed 10 pages. Please forward, as applicable, any capabilities, product, pricing information (for products, etc.), and/or other pertinent information to through email to kpz6@cdc.gov. Any responses should be emailed to kpz6@cdc.gov by April 3, 2024 at 12:00 PM. EST.